Quiz for Clinicians – Monitoring Patients on GLP-1 Therapy
Reviewed by: HU Medical Review Board | Last reviewed: September 2026 | Last updated: September 2026
Starting therapy is the straightforward part. These five questions cover what monitoring patients on GLP-1 therapy requires once treatment is established—nutritional status, the reaction that requires stopping, and two warnings whose scope is narrower than it looks.
Clinical Challenge
Which approach to nutritional monitoring is supported by current evidence for adults receiving glucagon-like peptide-1 (GLP-1) receptor agonists or dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists?
Clinical Challenge
A patient established on incretin therapy develops persistent severe abdominal pain radiating to the back. What do the labels in this class direct?
Clinical Challenge
An adult with compensated cirrhosis meets criteria for pharmacologic weight management and is being considered for a small-molecule oral GLP-1 receptor agonist. What does that agent's labeling state about hepatic impairment?
Clinical Challenge
What do the labels for the single-patient-use pens in this class direct regarding sharing a pen between two patients who are each prescribed therapy?
Clinical Challenge
Which patients do the diabetic retinopathy warnings in this class specifically direct clinicians to monitor?